Covista Inc.
CVSA
$132.33
-1.59%
Covista Inc. is an American healthcare educator operating five accredited institutions, serving over 97,000 students and addressing the U.S. healthcare workforce shortage through tech-enabled education. As a niche player in the for-profit education sector, it leverages a scalable model to expand access to healthcare careers. The current investor narrative centers on its growth trajectory amid rising demand for healthcare professionals, with recent quarterly results showing modest revenue growth and strong profitability, while the stock has experienced volatility, including a sharp decline in mid-July 2026. The company's focus on personalized, tech-enabled learning positions it to capitalize on structural workforce gaps, though regulatory and competitive dynamics remain key debates.…
CVSA
Covista Inc.
$132.33
Investment Opinion: Should I buy CVSA Today?
Based on the analysis, CVSA is rated a Buy. The stock offers a compelling risk/reward with a forward P/E of 13.03x, a PEG of 0.25x, and an average analyst target of $156.25, implying a 34.9% upside. The company's strong free cash flow of $336.28 million TTM and consistent profitability support the thesis that the recent pullback is overdone.
Sign up to view all
CVSA 12-Month Price Forecast
The AI assessment leans bullish, driven by the low forward P/E and PEG ratio, which suggest the market is underpricing growth. The strong free cash flow and consistent profitability provide a safety margin. However, the recent margin compression and modest revenue growth temper confidence, making the stance bullish but with medium confidence. If margins stabilize and revenue growth accelerates, the stance would be upgraded to high confidence; conversely, if margins deteriorate further, it would be downgraded to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Covista Inc.'s 12-month outlook, with a consensus price target around $159.50 and implied upside of +20.5% versus the current price.
Average Target
$159.50
0 analysts
Implied Upside
+20.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $175
Analyst target range
Analyst coverage is limited, with only 4 analysts providing targets, and the consensus recommendation is 'none' (likely a hold or neutral stance). The average target price is $156.25, implying an upside of 34.9% from the current price of $115.82. The target range spans from $140.00 (low) to $175.00 (high), with the high target suggesting a 51.1% upside, while the low target implies a 20.9% upside, indicating a generally bullish outlook despite the recent price decline. Institutional ratings from Barrington Research and Truist Securities have been consistently positive (Outperform and Buy) over the past year, with no downgrades, suggesting sustained confidence in the company's fundamentals.
Bulls vs Bears: CVSA Investment Factors
CVSA presents a mixed picture: strong profitability, low valuation on forward earnings, and bullish analyst targets contrast with a sharp recent price drop, margin compression, and modest revenue growth. The bull case is supported by a PEG of 0.25x and a 34.9% upside to the average target, while the bear case highlights operational deterioration and limited analyst backing. The most critical tension is whether the recent margin decline is temporary or a sign of structural cost pressures; if margins stabilize, the stock is likely undervalued, but if they continue to erode, the forward P/E could expand and the stock could fall further. Currently, the evidence slightly favors the bull case given the strong cash flow and analyst confidence, but the recent price action demands vigilance.
Bullish
- Undervalued on forward earnings: With a forward P/E of 13.03x versus a trailing P/E of 20.29x, the market is pricing in substantial earnings growth. The PEG ratio of 0.25x further suggests the stock is undervalued relative to its expected growth, making it attractive on a growth-adjusted basis.
- Strong analyst upside potential: The average analyst target price of $156.25 implies a 34.9% upside from the current price of $115.82, with the high target of $175.00 suggesting a 51.1% upside. Even the low target of $140.00 offers a 20.9% gain, indicating a bullish consensus despite the recent pullback.
- Consistent profitability and cash flow: The company has maintained positive net income across recent quarters, with Q3 FY2026 net income of $41.64 million and a trailing twelve-month free cash flow of $336.28 million. This financial stability supports ongoing investment in growth initiatives and provides a cushion against downturns.
- Stable gross margin above 56%: Gross margin has remained consistently above 56% over the past year, with Q3 FY2026 at 56.7%. This indicates strong pricing power and efficient cost management, providing a solid foundation for profitability even as the company scales.
Bearish
- Sharp price drop signals risk: The stock fell 12.33% on July 15, 2026, to $115.82, its lowest level in months, breaking below key support. This sudden decline may indicate negative sentiment or an impending fundamental issue, warranting caution.
- Margin compression in recent quarter: Net margin dropped from 15.2% in Q2 FY2026 to 8.5% in Q3, and operating margin fell from 22.1% to 18.9%. This deterioration suggests rising operating expenses or pricing pressures, which could weigh on future profitability if not reversed.
- Modest revenue growth: Revenue growth was only 4.5% year-over-year in Q3 FY2026, a slowdown from prior quarters. This tepid growth may not justify the premium valuation or the aggressive earnings growth implied by the forward P/E.
- Limited analyst coverage and neutral rating: With only 4 analysts covering the stock and a consensus recommendation of 'none' (likely hold/neutral), there is less external validation. The lack of strong buy ratings could limit upside momentum and increase uncertainty.
CVSA Technical Analysis
Over the past year, CVSA has exhibited a strong uptrend, with the stock trading at $115.82 as of July 15, 2026, down 12.33% from its 52-week high of $156.26 but well above its 52-week low of $86.97. The current price sits at approximately 74% of the 52-week range, indicating a pullback from recent highs but still in the upper half of the yearly range. This positioning suggests the stock is in a corrective phase within a longer-term bullish trend, though the recent decline warrants caution.
Beta
0.62
0.62x market volatility
Max Drawdown
-17.3%
Largest decline past year
52-Week Range
$87-$156
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CVSA Return | S&P 500 |
|---|---|---|
| 1m | +6.0% | +2.7% |
| 3m | +8.2% | +1.0% |
| 6m | +31.5% | +12.0% |
| 1y | — | +18.9% |
| ytd | — | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVSA Fundamental Analysis
Revenue for the most recent quarter (Q3 FY2026, ended March 31, 2026) was $487.03 million, up 4.5% year-over-year from $466.06 million in the prior-year quarter. This growth is modest but consistent, with revenue trending upward from $457.11 million in Q4 FY2025 to $503.39 million in Q2 FY2026, before a slight dip in Q3. The company's net income for Q3 was $41.64 million, down from $76.38 million in Q2, reflecting a net margin of 8.5% versus 15.2% in the prior quarter, indicating some margin compression. Gross margin remained stable at 56.7%, while operating margin was 18.9%, down from 22.1% in Q2, suggesting increased operating expenses.
Quarterly Revenue
$487030000.0B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
56.7%
Latest Quarter
Free Cash Flow
$336279000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVSA Overvalued?
Given that net income is positive, the PE ratio is the primary valuation metric. The trailing PE is 20.29x, while the forward PE is 13.03x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests an anticipated EPS increase of about 56%, which is aggressive but supported by analyst estimates of $11.04 EPS for the next fiscal year. The PEG ratio of 0.25x indicates the stock is undervalued relative to its growth rate, though this is based on forward estimates.
PE
17.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 9x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.54, which is moderate but not excessive, and a current ratio of 0.82, indicating potential liquidity concerns as current liabilities exceed current assets. The company's net margin fell to 8.5% in Q3 FY2026 from 15.2% in Q2, a significant drop that could signal rising costs or pricing pressure. Additionally, revenue growth of only 4.5% YoY suggests limited top-line momentum, which may not support the aggressive earnings growth implied by the forward P/E of 13.03x. Free cash flow remains positive at $336.28 million TTM, providing some buffer, but the margin trend warrants close monitoring.